Propanc Biopharma Reports Data Showing 90% Tumor Growth Inhibition with PRP in Pancreatic Cancer Models, Contrasting Profile with Revolution Medicines’ Daraxonrasib
(PRP's) deep tumor control, fewer metastases, a less fibrotic microenvironment, and chemo re-sensitization...RAS inhibition does not directly address